ChiCTR2100052177 版本V1.2 版本创建时间2022/04/24 11:39:50 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR2100052177 

最近更新日期:

Date of Last Refreshed on:

2022-04-24 11:38:45 

注册时间:

Date of Registration:

2021-10-20 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

乳腺癌保乳术同期联合局部组织瓣修复术中分层引流的临床观察

Public title:

The clinical observation of layered drainage during breast conserving surgery combined with local tissue flap repair

注册题目简写:

English Acronym:

研究课题的正式科学名称:

乳腺癌保乳术同期联合局部组织瓣修复术中分层引流的临床观察

Scientific title:

The clinical observation of layered drainage during breast conserving surgery combined with local tissue flap repair

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

李娜 

研究负责人:

陈文林 

Applicant:

Li Na 

Study leader:

Chen Wenlin 

申请注册联系人电话:

Applicant telephone:

+86 13629492728

研究负责人电话:

Study leader's
telephone:

+86 13888087395

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

linaarticle@163.com

研究负责人电子邮件:

Study leader's E-mail:

chenwenlin@aliyun.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

云南省昆明市西山区昆州路519号

研究负责人通讯地址:

云南省昆明市西山区昆州路519号

Applicant address:

519 Kunzhou Road, Xishan District, Kunming, Yunnan

Study leader's address:

519 Kunzhou Road, Xishan District, Kunming, Yunnan

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

云南省肿瘤医院

Applicant's institution:

Yunnan Cancer Hospital

研究负责人所在单位:

云南省肿瘤医院

Affiliation of the Leader:

Yunnan Cancer Hospital

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

KYLX202125

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

云南省肿瘤医院伦理委员会

Name of the ethic committee:

Ethics Committee of Yunnan Cancer Hospital

伦理委员会批准日期:

Date of approved by ethic committee:

2021-08-20 00:00:00

伦理委员会联系人:

许玉玲

Contact Name of the ethic committee:

Xu Yuling

伦理委员会联系地址:

云南省昆明市西山区昆州路519号

Contact Address of the ethic committee:

519 Kunzhou Road, Xishan District, Kunming, Yunnan

伦理委员会联系人电话:

Contact phone of the ethic committee:

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

云南省肿瘤医院

Primary sponsor:

Yunnan Cancer Hospital

研究实施负责(组长)单位地址:

云南省昆明市西山区昆州路519号

Primary sponsor's address:

519 Kunzhou Road, Xishan District, Kunming, Yunnan

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

云南

市(区县):

昆明

Country:

China

Province:

Yunnan

City:

Kunming

单位(医院):

云南省肿瘤医院

具体地址:

西山区昆州路519号

Institution
hospital:

Yunnan Cancer Hospital

Address:

519 Kunzhou Road, Xishan District

经费或物资来源:

云南省高层次卫生计划专业人才培养项目(D-2018002)

Source(s) of funding:

High-level Health and Family Planning Technical Experts Training Project of Yunnan Province (No:D-2018002)

研究疾病:

乳腺癌  

Target disease:

Breast Cancer

研究疾病代码:

Target disease code:

研究类型:

观察性研究

Study type:

Observational study

研究所处阶段:

回顾性研究 

Study phase:

Retrospective study

研究设计:

连续入组 

Study design:

Sequential 

研究目的:

主要目的:探讨乳腺癌保乳术同期联合局部组织瓣修复术中分层引流(组织瓣上+组织瓣下双管引流)与组织瓣下单管引流对术后引流量、置管时间及并发症发生率的影响。  

Objectives of Study:

Main purpose: To investigate the effect of stratified drainage (double-tube drainage on tissue flap + sub-tissue flap) and single-tube drainage under tissue flap on postoperative drainage volume, catheter placement time and complications in breast-conserving breast-conserving surgery combined with local tissue flap repair. impact on the incidence of disease.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

1.患者为女性,年龄≥18岁;
2.ECOG评分0-1分;
3.经病理组织学证实为乳腺的单侧或双侧原发性乳腺癌;
4.患者必须接受乳腺癌保乳术和局部组织瓣修复术;
5.术中留置1根及以上引流管;
6.术后引流信息记录完整且具备随访条件者;
7.心、脑、肺、肝、肾等重要脏器无重大疾病;
8.术前骨扫描、CT、彩超等检查排外远处转移征象

Inclusion criteria

1. The patient was female, aged ≥18 years; 2.ECOG score 0-1; 3. Unilateral or bilateral primary breast cancer confirmed by histopathology; 4. Patients must receive breast conserving surgery and local tissue flap repair; 5. One or more drainage tubes were indwelled during the operation; 6. Patients with complete postoperative drainage information and follow-up conditions; 7. No major diseases of heart, brain, lung, liver, kidney and other important organs; 8. Preoperative bone scan, CT, color ultrasound and other examinations exclude signs of distant metastasis

排除标准:

1.未行乳腺癌保乳术或术中未行局部组织瓣修复者;
2.行术中放疗者;
3.心、脑、肺、肝、肾等重要脏器具有重大疾病者;
4.术前骨扫描、CT、彩超等检查提示存在远处转移征象者;
5.活跃性神精系统疾病(精神分裂症,重度抑郁症,双向情感障碍等)患者;
6.活动性结缔组织病,如硬皮病,系统性红斑狼疮或胶原血管疾病;
7.不愿意签署知情同意书的;
8.无完全民事行为能力者;
9.在研究者看来,其他条件使他们不适合这项试验。

Exclusion criteria:

1. Those who have not received breast conserving surgery or local tissue flap repair during surgery; 2. Patients undergoing intraoperative radiotherapy; 3. Serious diseases of heart, brain, lung, liver, kidney and other important organs; 4. Preoperative bone scan, CT, color doppler ultrasound and other examinations suggest signs of distant metastasis; 5. Patients with active nervous system diseases (schizophrenia, major depression, bipolar disorder, etc.); 6. Active connective tissue diseases, such as scleroderma, systemic lupus erythematosus, or collagenous vascular diseases; 7. Not willing to sign informed consent; 8. Persons without full capacity for civil conduct; 9. In the researchers' view, other conditions made them unsuitable for the experiment.

研究实施时间:

Study execute time:

From 2021-11-01 00:00:00 To 2022-03-01 00:00:00  

征募观察对象时间:

Recruiting time:

From 2021-11-01 00:00:00 To 2022-03-01 00:00:00

干预措施:

Interventions:

组别:

case series

样本量:

97

Group:

case series

Sample size:

干预措施:

干预措施代码:

Intervention:

No

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

云南 

市(区县):

昆明 

Country:

China

Province:

Yunnan

City:

Kunming

单位(医院):

云南省肿瘤医院 

单位级别:

三级甲等 

Institution
hospital:

Yunnan Cancer Hospital

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

术后引流量

指标类型:

主要指标

Outcome:

Postoperative drainage volume

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

置管时间

指标类型:

主要指标

Outcome:

Disconnecting time

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

术后并发症发生率

指标类型:

主要指标

Outcome:

Incidence of complicationIs

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

组织:

Sample Name:

No

Tissue:

人体标本去向

其它  

说明

Fate of sample:

0thers  

Note:

征募研究对象情况:

Recruiting status:

正在进行

Recruiting

年龄范围:

Participant age:

最小 Min age 20 years
最大 Max age 70 years

性别:

女性

Gender:

Female

随机方法(请说明由何人用什么方法产生随机序列):

不适用

Randomization Procedure (please state who generates the random number sequence and by what method):

N/A

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

公开/Public

盲法:

Blinding:

试验完成后的统计结果(上传文件):

Calculated Results after
the Study Completed(upload file):

是否共享原始数据:

IPD sharing

否No

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

杂志发表

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

Publish

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

病例记录表

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Case Record Form,CRF

数据与安全监察委员会:

Data and Safety Monitoring Committee:

有/Yes

注册人:

Name of Registration:

 2021-10-20 23:47:23